Anlotinib

Researchers from Sylvester Comprehensive Cancer Center will deliver 9 oral presentations, 4 rapid oral presentations, and 51 poster presentations at the upcoming ASCO 2025 Annual Meeting, showcasing significant advances across multiple cancer types.

Global soft tissue sarcoma pipeline constitutes 125+ companies developing 130+ treatment therapies, with significant progress in clinical trials across various stages of development.

Dizal's JAK1 inhibitor golidocitinib combined with PD-1 antibodies achieved a 44.3% objective response rate in non-small cell lung cancer patients who progressed on prior anti-PD-1 therapy.

Akeso's gumokimab, an IL-17 targeting monoclonal antibody, has its NDA accepted by China's NMPA for treating moderate to severe plaque psoriasis.

A phase 2 trial, CTONG-1803/ALTER-LOO1, has demonstrated that combining anlotinib with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) significantly extends progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC) who have shown gradual, oligo, or potential progression after previous EGFR-TKI treatment. The study reported a median PFS of 9.1 months and a 12-month PFS rate of 38.8%, suggesting a feasible and effective treatment strategy for this patient population.